Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 7/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29243217 | 1.00 | ATM (0.41) | ATMPIK3CDALDH1A1RIPK1DPP4 | |
| SCHEMBL3950963 | 1.00 | ATM (0.41) | ATMPIK3CDALDH1A1RIPK1DPP4 | |
| SCHEMBL26906984 | 1.00 | ATM (0.41) | ATMPIK3CDALDH1A1RIPK1DPP4 | |
| SCHEMBL3469309 | 1.00 | ATM (0.41) | ATMPIK3CDALDH1A1RIPK1DPP4 | |
| SCHEMBL21959477 | 0.86 | ATM (0.49) | ATMPIK3CDALDH1A1RIPK1DPP4 | |
| SCHEMBL14426631 | 0.86 | ATM (0.49) | ATMPIK3CDALDH1A1RIPK1DPP4 | |
| SCHEMBL18516314 | 0.86 | ATM (0.49) | ATMPIK3CDALDH1A1RIPK1DPP4 | |
| SCHEMBL18426689 | 0.85 | ATM (0.36) | ATMPIK3CDALDH1A1RIPK1 | |
| SCHEMBL22557040 | 0.84 | MMP2 (0.42) | DPP4DPP8MMP2ANPEP | |
| SCHEMBL3955349 | 0.84 | MMP2 (0.42) | DPP4DPP8MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518952-B2 | 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors | PFIZER INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | ATM 1181/4885PIK3CD 394/4885ALDH1A1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.